California is currently home to 5612 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
Recruiting
This is a pilot study gathering and using samples and data from patients with gastrointestinal peritoneal carcinomatosis. Participants will be asked for permission to provide blood and ascites/peritoneal wash fluid, tumor samples during their planned surgical procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Peritoneal Carcinomatosis, Gastrointestinal Peritoneal Carcinomatosis
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
Recruiting
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS), Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: IC Study LLC, Escondido, California
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Recruiting
Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and t... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/24/2025
Locations: St. John's Regional Medical Center, Oxnard, California
Conditions: Acute Ischemic Stroke, Cerebral Stroke
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
Recruiting
The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/24/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Chronic Pancreatitis
ExoLuminate Study for Early Detection of Pancreatic Cancer
Recruiting
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Biological Dynamics, San Diego, California
Conditions: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110), San Francisco, California
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: UC Irvine Health Cancer Center-Newport, Costa Mesa, California
Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Regeneron AA Multicenter (Dupilumab)
Recruiting
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of California, Irvine, Irvine, California
Conditions: Alopecia Areata
Writing About Experiences and Health in Older Adults II
Recruiting
UCLA researchers looking for healthy older adults (aged 65+) to participate in a study investigating how writing about experiences can affect your brain and body. Once a week for 6 weeks, participants will write about their experiences and fill out online questionnaires. Participants will also come to the UCLA campus to complete a neuroimaging session (fMRI), provide a blood spot sample, and fill out questionnaires 2 times: once prior to the 6-week writing period and once immediately after the... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2025
Locations: Center for Cognitive Neuroscience, Los Angeles, California
Conditions: Social Psychology
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Recruiting
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of California San Diego - Moores Cancer Center, La Jolla, California
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Recruiting
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2). Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: California Cancer Associates for Research & Excellence, Inc., Encinitas, California
Conditions: Colorectal Cancer